URGN (UroGen Pharma Ltd) Cumulative Company Assets

Official company branding of UroGen Pharma Ltd (URGN)

This daily price chart for UroGen Pharma Ltd. (URGN) reflects total assets, which currently stand at 230.66. UroGen Pharma Ltd. (URGN) is developing an innovative hydrogel for the therapy of urological tumors, ensuring high margins and a steady cash flow. Patents for RTGel technology and FDA certification create a powerful moat against competitors. Additionally, the business is implementing molecular drug design automation while maintaining scientist control over clinical trials.

UroGen Pharma Ltd (URGN) Aggregate Company Assets: for the period 07/04/2022 - 10/31/2026

Financial and market metric breakdowns for UroGen (URGN)

- stock quotes and analyst forecast:
Share Price urogen.com|URGN - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation UroGen Pharma Corp|URGN - Enterprise Value
- company book value details:
Book Value per Share UroGen Pharma|URGN - Company Book Value|Capitalization to Book Value Ratio urogen.com|URGN - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio UroGen Pharma Ltd.|URGN - Long-Term Debt to Capital|Current Liabilities to Capital UroGen Pharma Corp|URGN - Company Debts|Debt to Net Assets Ratio UroGen Pharma Corp|URGN - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings UroGen Pharma|Quick Liquidity Indicator urogen.com
- earnings and market multiples details:
URGN - Net Income
Basic company analysis:urogen.com (URGN)
Core merchandise of UroGen Pharma

For UroGen Pharma Ltd. (URGN), which focuses on independently bringing its drug to market without M&A activity, resource dynamics determine the company's ability to scale commercialization. This assessment of controlled resources is calculated inversely via ROA, combining equity and liabilities to identify the real value of the balance sheet, where steady growth confirms a strengthening fundamental without excessive debt risk.

Key competitors

Total Business Assets ONC|HALO (Halozyme) - Company Total Assets|Cumulative Company Assets Revolution Medicines Inc (RVMD)|Company Total Assets AAPG|Company Total Assets CG Oncology Therapeutics (CGON)|Aggregate Company Assets Bicara Therapeutics Inc. BCAX|PSNL: Total Business Assets|Erasca - Company Total Assets|Delcath Systems Inc (DCTH) - Cumulative Company Assets|YMAB: Company Total Assets|Company Assets Aura Corp (AURA)|Aggregate Company Assets Candel Therapeutics Inc.|ARAY: Aggregate Asset Value|Cumulative Company Assets SLS (SELLAS Life Sciences)|ACTU (Actuate Therapeutics Inc.) - Aggregate Asset Value|Company Total Assets CTOR (Citius Oncology, Inc)|HURA - Cumulative Company Assets|TARA: Cumulative Company Assets|FATE - Company Total Assets|aadibio.com (WHWK) - Aggregate Company Assets|TScan Therapeutics, Inc. - Aggregate Asset Value|CSBR (Champions Oncology Inc) - Company Total Assets|Company Assets XBiotech USA XBIT|Cumulative Company Assets CVM (CEL-SCI Corporation)|Company Total Assets ostherapies.com (OSTX)|Aggregate Company Assets Radiopharm Theranostics RADX|Aggregate Asset Value ARTV|ANL - Aggregate Company Assets|Company Assets Veru Corporation|TPST: Company Total Assets|Company Balance Sheet Assets Xilio Therapeutics XLO|RENB (Renovaro Biosciences) - Company Total Assets|Company Assets Mural Bio MURA|Aggregate Company Assets Kairos Pharma Ltd (KAPA)|onkuretherapeutics.com - Total Business Assets|CytoMed Therapeutics Limited - Cumulative Company Assets|Aggregate Asset Value CRIS|APLM - Aggregate Company Assets|Total Asset Value of Company THAR|ADVB: Company Total Assets|Genprex Inc - Aggregate Asset Value|CLDI (Calidi Biotherapeutics Inc.) - Company Total Assets|Company Total Assets sunshinebiopharma.com|Aggregate Company Assets Xenetic Biosciences (XBIO)|SLRX (Salarius Pharmaceuticals Inc) - Aggregate Asset Value|Aggregate Company Assets Purple Biotech Corp PPBT|AONC - Cumulative Company Assets|BeiGene, Ltd. - Company Total Assets|CKPT - Company Total Assets|ELEV (Elevation Oncology) - Cumulative Company Assets|iCAD - Aggregate Asset Value|Aggregate Company Assets Ikena Oncology Inc.|Aggregate Company Assets NTBL|Cumulative Company Assets VIRX (Viracta Therapeutics)|Aggregate Business Assets MOR|Company Total Assets NAYA (NAYA Biosciences Inc.)|AAPGV: Total Business Assets